Dyne Therapeutics, Inc.

NASDAQ:DYN

Biotechnology

Healthcare
$15.87 +1.97%

+$0.38 today

Market cap
$2.97B
Beta
1.08
P/E (TTM)
-7.2
EPS (TTM)
-$2.74
52W Low $8.06High $25.00

Volume 2.93M

Average 1.71M

DYN Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Dyne Therapeutics, Inc.NASDAQ: DYN

Weighted Avg Shares (Diluted) · Q2 FY2026 · quarter ended Jun 2026

Weighted avg shares (diluted) growth accelerates

Q2 FY2026 weighted avg shares (diluted) of 165.45M shares rose 45.3% year over year, ahead of the +40.8% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 0.3% from the prior quarter. Over 3 fiscal years it compounded at +35.2% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +45.3% holds above the trailing-twelve-month pace of +40.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
165.45M+0.3% QoQ
Last fiscal yearDec 2025
128.44M+36.4% YoY
LTMJun 2026
150.19M+40.8% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+45.3%——
1 year+36.4%——
3-year CAGR+35.2%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
128.44M USD
Year-over-year change
+36.4%
4-year CAGR
+26.0%

Weighted Avg Shares (Diluted) vs competitors

How DYN compares with its peers on the latest reported figures

  • DYN's LTM Jun 2026 weighted avg shares (diluted) of 150.19M shares is the 3rd highest of the 11 companies compared; the peer median is 81.88M shares.
  • Its year-over-year change of +40.8% is the 2nd highest of 11, against a peer median of +11.2%.
  • Over three fiscal years its annual growth of +35.2% compares with a peer median of +19.4%.
DYN Competitors Peer median
Weighted Avg Shares (Diluted) for DYN and competitors
Company Period LTM YoY 3-year CAGR
WVEWave Life Sciences Ltd.LTM Mar 2026178.01M +19.3%+28.8%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026164.62M -0.2%+4.1%
DYNDyne Therapeutics, Inc.LTM Jun 2026150.19M +40.8%+35.2%
SRPTSarepta Therapeutics, Inc.LTM Mar 2026108.39M +6.9%+6.2%
SLDBSolid Biosciences Inc.LTM Mar 202698.28M +94.3%+117.4%
PTCTPTC Therapeutics, Inc.LTM Jun 202685.59M +7.4%+7.2%
LRMRLarimar Therapeutics, Inc.LTM Mar 202678.18M +22.5%+41.5%
STOKStoke Therapeutics, Inc.LTM Mar 202659.6M +4.3%+15.0%
CAPRCapricor Therapeutics, Inc.LTM Mar 202649.43M +35.6%+23.7%
TRDAEntrada Therapeutics, Inc.LTM Mar 202641.5M +3.6%+9.8%
PEPGPepGen Inc.LTM Mar 202637.49M +15.0%+39.2%
Peer median (excluding DYN) 81.88M+11.2%+19.4%

Competitors are the stored peer set for DYN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue002.46M2.24M2.05M
Gross Profit00(2.46M)(2.24M)(2.05M)
Gross Margin—————
Research & Development121.31M142.76M210.76M281.41M398.33M
Selling, General & Admin28.72M28.2M31.4M62.48M69.85M
Operating Expenses150.03M170.96M239.7M341.64M466.14M
Depreciation & Amortization1.09M1.68M1.67M1.67M2.05M
EBITDA(148.2M)(163.5M)(234.26M)(315.75M)(437.97M)
EBITDA Margin—————
Operating Income(150.03M)(170.96M)(242.16M)(343.89M)(468.18M)
Operating Margin—————
Interest Income742K2.92M7.64M26.92M29.86M
Interest Expense02.92M006.19M
Other Income / Expenses734K2.86M6.23M26.47M21.97M
Income Before Tax(149.29M)(168.1M)(235.94M)(317.42M)(446.21M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(149.29M)(168.1M)(235.94M)(317.42M)(446.21M)
Net Margin—————
EPS (Basic)(2.93)(3.23)(3.95)(3.37)(3.47)
EPS (Diluted)(2.93)(3.23)(3.95)(3.37)(3.47)
Weighted Avg Shares50.9M51.98M59.68M94.14M128.44M
Weighted Avg Shares (Diluted)50.9M51.98M59.68M94.14M128.44M

Dyne Therapeutics, Inc.

NASDAQ:DYN

Intrinsic Alpha fair value

Locked

Current Price

$15.87

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.